Thursday 16 October, 2025
Introduction and Objectives: Immuno-oncology (IO) therapeutic strategies, such as oncolytic viruses (OVs), are based on the activation of the endogenous anti-tumor…
Read moreOral: Drug/Disease Modelling - Oncology
AN INCIDENCE-SEVERITY MODEL FOR CYTOKINE RELEASE SYNDROME FOLLOWING DOSE-PRIMING REGIMENS OF ELRANATAMAB
Thursday 16 October, 2025
Introduction: Cytokine Release Syndrome (CRS) is a common adverse event with bispecific antibody (BsAb) therapy. Dose-priming regimens are routinely devised…
Read moreDevelopment of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental design
Thursday 16 October, 2025
Introduction: Chimeric antigen receptor-T cell (CAR-T) therapy is a novel cellular immunotherapy and has achieved impressive treatment outcomes for many…
Read moreOptimizing Sunitinib Dosing in mRCC: Addressing Confounding Bias and Immortal Time Bias in Exposure- and Toxicity-survival Analyses using a Multistate Survival Modeling Framework
Thursday 16 October, 2025
Objectives: Sunitinib was approved by the FDA in 2006 and remains the most cost-effective first-line treatment for metastatic renal cell…
Read more